Replies to post #324085 on Avid Bioservices Inc (CDMO)

[swg_tdr]

h, North does this blow away any Bavi residuals?

and is there a peripheral lock-in of the PS patents?

PS, an anionic phospholipid tightly segregated to the internal surface of the plasma membrane of resting mammalian cells, has been reported to be exposed on vascular ECs in tumors.11, 16, 31, 32 This externalized anionic phospholipid on hitherto viable cells has been identified as one of the most specific markers of tumor vasculature.3, 4, 7, 33, 34 Because PS is also expressed constitutively on some TCs,4 it prompted us to test the anticancer effect of PC-SA liposomes, a novel carrier having strong affinity for PS. In this study, we unravel a distinguishing tumoricidal activity of PC-SA liposomes in vitro and in vivo. Entrapment of established drugs, DOX and CPT, in these vesicles enhanced their efficacies for almost complete remission. The anticancer activity of these liposomes involves specific interaction of PC-SA with induction of apoptosis in PS-overexpressing cells.

In this study, cationic liposomes of reproducible size (146 nm) and charge (+52 mV) composed of PC and SA were utilized to target PS exposed on TCs. PC-SA as a monotherapy demonstrates 50%–96% killing activity on multiple cancer cell lines (patent application number WO2015040636A1

well the mice are running in another direction now

obviously the patent is Anderson's and a Bavi competitor will pick it up.


best,
N